Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Beijing Med-Pharm completes private placement of senior promissory notes
The offering, which raised gross proceeds of $23.1 million, includes warrants with a five-year term to purchase an aggregate of 575,000 shares of common stock of the company,
The offering, which raised gross proceeds of $23.1 million, includes warrants with a five-year term to purchase an aggregate of 575,000 shares of common stock of the company,
The purchase will include the transfer of know-how, intellectual property, inventory and technology from Micrus to Merit. John Kilcoyne, chairman and CEO of Micrus, said: “This divestiture allows
Assets include the Confidence system, which consists of a proprietary delivery system and a novel polymethylmethacrylate bone cement that can be injected directly into vertebral bodies to treat
Under the terms of the agreement, Lantibio will conduct the development program and filing of the new drug application (NDA), while Alcon will assume responsibility for subsequent marketing,
Gordon Sherriff, COO of Angel Biotechnology, said: “We are delighted that Materia Medica, a leading Russian pharmaceutical company, has decided to award a second contract to Angel, so
The new pain product combines the effects of a centrally acting analgesic, codeine, with a peripherally acting analgesic, acetaminophen, in a unique strength previously not available. The product
Neuronal nicotinic receptors (NNRs) are a class of receptors found in the nervous system that play a critical role in modulating the release of chemicals called neurotransmitters to
More than 75% of patients treated in the study achieved tumor reductions across all dose levels evaluated, including four with partial responses, 12 additional patients had stable disease
The approval was based on the exceptional safety profile of Rexin-G in the first 18 patients who participated in the US-based clinical trials, and the profound demonstration of
MB07811 reduced hepatic fat content in all animal models tested while T3, the natural TR ligand, failed to reduce hepatic fat content in two of the three models.